데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
133865-89-1C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=ONEMGRZFTLSKBAP-LBPRGKRZSA-NSafinamide is an amino acid amide.
133865-89-1DTXSID601010282CHEMBL396778CHEBI:134718Pharmaceuticals -> Listed in ZINC15
Pharmaceuticals -> Nervous system -> Anti-parkinson drugs
Breastfeeding; Lactation; Antiparkinson Agents; Monoamine Oxidase Inhibitors;
FDA approved drugs -> Active ingredient
EMA approved medicines: Human medicine
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
Danger
H301 (90.5%): Toxic if swallowed [Danger Acute toxicity, oral]
P264, P264+P265, P270, P273, P280, P301+P316, P305+P354+P338, P317, P321, P330, P391, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 42 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Safinamide has been reported to cause serum enzyme elevations in a small proportion of patients treated long term, although the abnormalities were usually mild and self-limiting and were usually no more frequent than with placebo or comparator agents. Safinamide has not been implicated in cases of acute liver injury, but such instances have been reported with nonspecific MAO inhibitors.
N04BD03
N - Nervous system
QN - Nervous system
Safinamide is a unique molecule with multiple mechanisms of action and a very high therapeutic index. It combines potent, selective, and reversible inhibition of MAO-B with blockade of voltage-dependent Na+ and Ca2+ channels and inhibition of glutamate release. Safinamide has neuroprotective and neurorescuing effects in MPTP-treated mice, in the rat kainic acid, and in the gerbil ischemia model.
The principal step is mediated by amidases which have not been identified, and produces safinamide acid. It is also metabolized to O-debenzylated safinamide and N-delkylated amine. The N-dealkylated amine is then oxidized to a carboxylic acid and finally glucuronidated. Dealkylation reactions are mediated by cytochrome P450s (CYPs), especially CYP3A4. Safinamide acid binds to organic anion transporter 3 (OAT3), but no clinical relevance of this interaction has been determined. Safinamide also binds to ABCG2 transiently. No other transporter affinities have been found in preliminary studies.
90ENL74SIG
SAFINAMIDE
Established Pharmacologic Class [EPC] - Monoamine Oxidase Type B Inhibitor
Mechanisms of Action [MoA] - Monoamine Oxidase-B Inhibitors
Mechanisms of Action [MoA] - Breast Cancer Resistance Protein Inhibitors
Safinamide is a Monoamine Oxidase Type B Inhibitor. The mechanism of action of safinamide is as a Monoamine Oxidase-B Inhibitor and Breast Cancer Resistance Protein Inhibitor.
Rapid with peak plasma concentrations ranging from 2 to 4 h, total bioavailability is 95%. Food prolonged the rate and did not affect the extent of absorption of safinamide.
76% renal, 1.5% faeces
1.8 litres/kg
total oral clearance of plasma , which accounts for parent safinamide as well as metabolites, was on average only 17.53 ± 2.71 ml/h × kg
역사Safinamide is an α-aminoamide derivative with a multimodal mechanism of action involving both dopaminergic and non-dopaminergic properties. It increases levels of available dopamine through dopamine reuptake inhibition andMAO-B inhibition. It is a potent and reversible inhibitor of MAO-B, with significantly greater selectivity for MAO-B over MAO-A than selegiline and rasagiline. However, it also has an important and novel mode of action that involves blockade of Na+ channels andmodulation of Ca2+ channels that inhibits glutamate release and therefore may provide a level of cognitive improvement and neuroprotection. Homeostatic interactions between dopamine and glutamate are central to the normal physiology of the basal ganglia. In PD, this relationship is altered, resulting in upregulation of cortico-striatal glutamatergic function in l-dopa-induced dyskinesia. Any drug that can counteract such unbalance in glutamate function is potentially useful in controlling dyskinesias. Safinamide was originated by Farmitalia Carlo Erba, a company that was later purchased by Pharmacia. Newron Pharmaceuticals was established as a spin-off of Pharmacia in 1999 and acquired safinamide rights and intellectual property from Pharmacia Corporation. Newron originally granted Serono exclusive worldwide rights to develop, manufacture, and commercialize safinamide in 2006. However, in October 2011, Merck Serono agreed to return full global rights for safinamide to Newron. Newron then finalized a strategic collaboration and license agreement with Zambon for the worldwide development and commercialization of safinamide.